Shares of Galectin Therapeutics Inc. (NASDAQ:GALT – Get Free Report) passed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $1.85 and traded as high as $2.10. Galectin Therapeutics shares last traded at $2.08, with a volume of 137,118 shares.
Analysts Set New Price Targets
Separately, StockNews.com upgraded Galectin Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, November 20th.
Check Out Our Latest Report on GALT
Galectin Therapeutics Stock Performance
Institutional Investors Weigh In On Galectin Therapeutics
Several hedge funds and other institutional investors have recently modified their holdings of GALT. Citadel Advisors LLC lifted its holdings in Galectin Therapeutics by 269.5% during the 3rd quarter. Citadel Advisors LLC now owns 18,140 shares of the company’s stock valued at $29,000 after buying an additional 28,840 shares in the last quarter. Centaurus Financial Inc. bought a new stake in shares of Galectin Therapeutics during the first quarter valued at approximately $34,000. Retirement Guys Formula LLC boosted its holdings in shares of Galectin Therapeutics by 87.0% in the fourth quarter. Retirement Guys Formula LLC now owns 21,500 shares of the company’s stock valued at $36,000 after purchasing an additional 10,000 shares during the period. Jane Street Group LLC bought a new position in Galectin Therapeutics in the fourth quarter worth approximately $40,000. Finally, Beacon Capital Management LLC increased its holdings in Galectin Therapeutics by 89.6% during the 4th quarter. Beacon Capital Management LLC now owns 23,905 shares of the company’s stock worth $40,000 after purchasing an additional 11,300 shares during the period. 12.24% of the stock is currently owned by hedge funds and other institutional investors.
Galectin Therapeutics Company Profile
Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer.
Featured Articles
- Five stocks we like better than Galectin Therapeutics
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- How to Use Options Collars to Hedge Your Stock Gains
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Palantir Stock Spikes 6% on U.S. Army TITAN Contract
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- AeroVironment Stock Rockets To New High: Price Could Double Again
Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.